1.220USDMkt Cap: 5.93M USDP/E: —Last update: 2026-05-21
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap5.93M USD
Enterprise Value5.19M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.22M USD
Revenue/Share—
Last Price1.220 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.21
EV/Revenue—
P/S—
P/B-0.02
EPS (TTM)-1177.89
EPS (Forward)—
52W Range
1.14040% of range1.340
52W High1.340 USD
52W Low1.140 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE547.06%
ROA-694.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.55M USD
CapEx (TTM)2.40M USD
FCF Margin—
FCF Yield88.08%
Net Debt-734.00K USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity-0.11
Current Ratio0.34
Quick Ratio0.12
Book Value/Sh-77.8160 USD
Cash/Share0.3110 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateMar 27, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.86M
Float2.29M
Insiders77.87%
Institutions0.00%
Short Interest
Short Ratio0.2d
Short % Float1.15%
Short % Out.0.60%
Shares Short29.31K
Short (prev mo.)92.36K
Technical
SMA 505.218 (-76.6%)
SMA 20075.27 (-98.4%)
Beta1.57
S&P 52W Chg28.31%
Avg Vol (30d)308.51K
Avg Vol (10d)217.88K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—